 Enhancer of Zeste Homolog 2 Protein
"Enhancer of Zeste Homolog 2 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A histone-lysine N-methyltransferase and catalytic subunit of Polycomb Repressive Complex 2. It methylates LYSINE 9 (H3K9me) and LYSINE 27 (H3K27me) of HISTONE H3, leading to transcriptional repression of the affected target gene. EZH2 also methylates non-histone proteins such as GATA4 TRANSCRIPTION FACTOR and the nuclear receptor RORA. It regulates CIRCADIAN CLOCKS via histone methylation at the PROMOTER REGIONS of the circadian genes and its repressive activity is also important for the identity and differentiation of EMBRYONIC STEM CELLS.
| Descriptor ID |
D000071221
|
| MeSH Number(s) |
D05.500.781.750.250 D08.811.913.555.500.800.400.500.500 D12.776.660.235.600.200.250 D12.776.664.235.800.200.250 D12.776.930.780.890.200.250
|
| Concept/Terms |
Enhancer of Zeste Homolog 2 Protein- Enhancer of Zeste Homolog 2 Protein
- Lysine N-Methyltransferase-6
- Lysine N Methyltransferase 6
- Histone-Lysine N-Methyltransferase EZH2
- EZH2, Histone-Lysine N-Methyltransferase
- Histone Lysine N Methyltransferase EZH2
- Enhancer of Zeste Homolog 2
|
Below are MeSH descriptors whose meaning is more general than "Enhancer of Zeste Homolog 2 Protein".
Below are MeSH descriptors whose meaning is more specific than "Enhancer of Zeste Homolog 2 Protein".
This graph shows the total number of publications written about "Enhancer of Zeste Homolog 2 Protein" by people in this website by year, and whether "Enhancer of Zeste Homolog 2 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2012 | 0 | 2 | 2 | | 2013 | 0 | 2 | 2 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 2 | 2 | | 2016 | 1 | 0 | 1 | | 2017 | 1 | 2 | 3 | | 2018 | 2 | 2 | 4 | | 2019 | 1 | 2 | 3 | | 2020 | 1 | 1 | 2 | | 2021 | 1 | 0 | 1 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Enhancer of Zeste Homolog 2 Protein" by people in Profiles.
-
Song J, Gooding AR, Hemphill WO, Love BD, Robertson A, Yao L, Zon LI, North TE, Kasinath V, Cech TR. Structural basis for inactivation of PRC2 by G-quadruplex RNA. Science. 2023 09 22; 381(6664):1331-1337.
-
Shishido K, Purvis IJ, Velpula KK, Venkataraman S, Vibhakar R, Asuthkar S. Targeting B7-H3 through EZH2 inhibition in MYC-positive Group 3 medulloblastoma. Oncol Rep. 2023 Jun; 49(6).
-
Kraft K, Yost KE, Murphy SE, Magg A, Long Y, Corces MR, Granja JM, Wittler L, Mundlos S, Cech TR, Boettiger AN, Chang HY. Polycomb-mediated genome architecture enables long-range spreading of H3K27 methylation. Proc Natl Acad Sci U S A. 2022 05 31; 119(22):e2201883119.
-
Qi L, Lindsay H, Kogiso M, Du Y, Braun FK, Zhang H, Guo L, Zhao S, Injac SG, Baxter PA, Su JM, Xiao S, Erickson SW, Earley EJ, Teicher B, Smith MA, Li XN. Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies. Lab Invest. 2022 02; 102(2):185-193.
-
Soto RA, Najia MAT, Hachimi M, Frame JM, Yette GA, Lummertz da Rocha E, Stankunas K, Daley GQ, North TE. Sequential regulation of hemogenic fate and hematopoietic stem and progenitor cell formation from arterial endothelium by Ezh1/2. Stem Cell Reports. 2021 07 13; 16(7):1718-1734.
-
Kurmasheva RT, Erickson SW, Earley E, Smith MA, Houghton PJ. In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium. Pediatr Blood Cancer. 2021 02; 68(2):e28772.
-
Yuan H, Han Y, Wang X, Li N, Liu Q, Yin Y, Wang H, Pan L, Li L, Song K, Qiu T, Pan Q, Chen Q, Zhang G, Zang Y, Tan M, Zhang J, Li Q, Wang X, Jiang J, Qin J. SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways. Cancer Cell. 2020 09 14; 38(3):350-365.e7.
-
Li J, Wang W, Zhang Y, Cieslik M, Guo J, Tan M, Green MD, Wang W, Lin H, Li W, Wei S, Zhou J, Li G, Jing X, Vatan L, Zhao L, Bitler B, Zhang R, Cho KR, Dou Y, Kryczek I, Chan TA, Huntsman D, Chinnaiyan AM, Zou W. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. J Clin Invest. 2020 05 01; 130(5):2712-2726.
-
Khan N, Schoenike B, Basu T, Grabenstatter H, Rodriguez G, Sindic C, Johnson M, Wallace E, Maganti R, Dingledine R, Roopra A. A systems approach identifies Enhancer of Zeste Homolog 2 (EZH2) as a protective factor in epilepsy. PLoS One. 2019; 14(12):e0226733.
-
Wang X, Long Y, Paucek RD, Gooding AR, Lee T, Burdorf RM, Cech TR. Regulation of histone methylation by automethylation of PRC2. Genes Dev. 2019 10 01; 33(19-20):1416-1427.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|